08 January 2026
08 January 2026
The deal marks Lilly’s first in the M&A arena in 2026 as the company diversifies its pipeline beyond obesity drugs.
GSK will be filing for approval of bepirovirsen in hepatitis B to global regulatory authorities based on the Phase III data.
Fibryga is a human plasma-derived fibrinogen concentrate authorised for AFD in the US.
The deal was first announced in November 2025 and had a total equity value of approximately $129m at closing.
According to Citi analysts, Amgen’s acquisition of Dark Blue could further drive the strength of Amgen’s early oncology pipeline.
Nimbus will apply its computational chemistry and structure-based drug design to a discovery programme in obesity treatment.
CK0804 is an allogeneic, off‑the‑shelf Treg cell therapy.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
